[1]
|
Kelly, M.E., Spolverato, G., Le, G., Mavros, M.N., Doyle, F., Pawlik, T.M. and Winter, D.C. (2014) Synchronous Colorectal Liver Metastasis: A Network Meta-Analysis Review Comparing Classical, Combined, and Liver-First Surgical Strategies. Journal of Surgical Oncology, 111, 341-351. https://doi.org/10.1002/jso.23819
|
[2]
|
Rosen, L.S., Jacobs, I.A. and Burkes, R.L. (2017) Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Targeted Oncology, 12, 599-610. https://doi.org/10.1007/s11523-017-0518-1
|
[3]
|
Conroy, T., Borg, C., et al. (2021) Neoadjuvant Chemotherapy with FOLFIRINOX and Preoperative Chemoradiotherapy for Patients with Locally Advanced Rectal Cancer (UNICANCER-PRODIGE 23): A Multicentre, Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 22, 702-715.
|
[4]
|
Vulasala, S.S.R., Sutphin, P.D., Kethu, S., Onteddu, N.K. and Kalva, S.P. (2023) Interventional Radiological Therapies in Colorectal Hepatic Metastases. Frontiers in Oncology, 13, Arti963966. https://doi.org/10.3389/fonc.2023.963966
|
[5]
|
Ma, B., Gao, P., Wang, H., Xu, Q., Song, Y., Huang, X., Sun, J., Zhao, J., Luo, J., Sun, Y. and Wang, Z. (2017) What Has Preoperative Radio(Chemo)Therapy Brought to Localized Rectal Cancer Patients in Terms of Perioperative and Long-Term Outcomes over the Past Decades? A Systematic Review and Meta-Analysis Based on 41,121 Patients. International Journal of Cancer, 141, 1052-1065. https://doi.org/10.1002/ijc.30805
|
[6]
|
Van Tilborg, A.A.J.M., Meijerink, M.R., Sietses, C., Van Waesberghe, J.H.T.M., Mackintosh, M.O., Meijer, S., Van Kuijk, C. and Van Den Tol, P. (2011) Long-Term Results of Radiofrequency Ablation for Unresectable Colorectal Liver Metastases: A Potentially Curative Intervention. British Journal of Radiology, 84, 556-565. https://doi.org/10.1259/bjr/78268814
|
[7]
|
Zacharakis, M., Xynos, I.D., Lazaris, A., et al. (2010) Predictors of Survival in Stage IV Metastatic Colorectal Cancer. Anticancer Research, 30, 653-660.
|
[8]
|
Heinemann, V., Von Weikersthal, L.F., Decker, T., et al. (2014) FOLFIRI plus Cetuximab versus FOLFIRI plus Bevacizumab as First-Line Treatment for Patients with Metastatic Colorectal Cancer (FIRE-3): A Randomised, Open-Label, Phase 3 Trial. The Lancet Oncology, 15, 1065-1075. https://doi.org/10.1016/S1470-2045(14)70330-4
|
[9]
|
Yoshino, T., Watanabe, J., Shitara, K., et al. (2022) Panitumumab (PAN) plus MFOLFOX6 versus Bevacizumab (BEV) plus MFOLFOX6 as First-Line Treatment in Patients with RAS Wild-Type (WT) Metastatic Colorectal Cancer (MCRC): Results from the Phase 3 PARADIGM Trial. JCO, 40, LBA1. https://doi.org/10.1200/JCO.2022.40.17_suppl.LBA1
|
[10]
|
Denda, T., Sakai, D., Hamaguchi, T., et al. (2019) Phase II Trial of Aflibercept with FOLFIRI as a Second-Line Treatment for Japanese Patients with Metastatic Colorectal Cancer. Cancer Science, 110, 1032-1043. https://doi.org/10.1111/cas.13943
|
[11]
|
Tampellini, M., Sonetto, C. and Scagliotti, G.V. (2016) Novel Anti-Angiogenic Therapeutic Strategies in Colorectal Cancer. Expert Opinion on Investigational Drugs, 25, 507-520. https://doi.org/10.1517/13543784.2016.1161754
|
[12]
|
Wilhelm, S.M., Dumas, J., Adnane, L., Lynch, M., Carter, C.A., Schütz, G., Thierauch, K.-H. and Zopf, D. (2011) Regorafenib (BAY 73-4506): A New Oral Multikinase Inhibitor of Angiogenic, Stromal and Oncogenic Receptor Tyrosine Kinases with Potent Preclinical Antitumor Activity. International Journal of Cancer, 129, 245-255. https://doi.org/10.1002/ijc.25864
|
[13]
|
Grothey, A., Van Cutsem, E., Sobrero, A., et al. (2013) Regorafenib Monotherapy for Previously Treated Metastatic Colorectal Cancer (CORRECT): An International, Multicentre, Randomised, Placebo-Controlled, Phase 3 Trial. The Lancet, 381, 303-312. https://doi.org/10.1016/S0140-6736(12)61900-X
|
[14]
|
Burki, T.K. (2018) Fruquintinib for Previously Treated Metastatic Colorectal Cancer. The Lancet Oncology, 19, e388. https://doi.org/10.1016/S1470-2045(18)30503-5
|
[15]
|
Li, J., Qin, S., Xu, R., et al. (2018) Effect of Fruquintinib vs Placebo on Overall Survival in Patients with Previously Treated Metastatic Colorectal Cancer: The FRESCO Randomized Clinical Trial. JAMA, 319, 2486-2496. https://doi.org/10.1001/jama.2018.7855
|
[16]
|
Venook, A.P., Niedzwiecki, D., Innocenti, F., Fruth, B., Greene, C., O’Neil, B.H. and Lenz, H.-J. (2016) Impact of Primary (1˚) Tumor Location on Overall Survival (OS) and Progression-Free Survival (PFS) in Patients (Pts) with Metastatic Colorectal Cancer (MCRC): Analysis of CALGB/SWOG 80405 (Alliance). Journal of Clinical Oncology, 34, 3504-3504. https://doi.org/10.1200/JCO.2016.34.15_suppl.3504
|
[17]
|
Peeters, M., Price, T.J., Cervantes, A., et al. (2014) Final Results from a Randomized Phase 3 Study of FOLFIRI ± Panitumumab for Second-Line Treatment of Metastatic Colorectal Cancer. Annals of Oncology, 25, 107-116. https://doi.org/10.1093/annonc/mdt523
|
[18]
|
Strickler, J.H., Van Cutsem, E., et al. (2023) Tucatinib plus Trastuzumab for Chemotherapy-Refractory, HER2-Positive, RAS Wild-Type Unresectable or Metastatic Colorectal Cancer (MOUNTAINEER): A Multicentre, Open-Label, Phase 2 Study. The Lancet Oncology, 24, 496-508.
|
[19]
|
Ciombor, K.K., Strickler, J.H., Bekaii-Saab, T.S., et al. (2022) BRAF-Mutated Advanced Colorectal Cancer: A Rapidly Changing Therapeutic Landscape. JCO, 40, 2706-2715. https://doi.org/10.1200/JCO.21.02541
|
[20]
|
Marabelle, A., Le, D.T., Ascierto, P.A., et al. (2020) Efficacy of Pembrolizumab in Patients with Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results from the Phase II KEYNOTE-158 Study. JCO, 38, 1-10. https://doi.org/10.1200/JCO.19.02105
|
[21]
|
Maio, M., Ascierto, P.A., Manzyuk, L., et al. (2021) Pembrolizumab in Microsatellite Instability High (MSI-H)/Mismatch Repair Deficient (DMMR) Cancers: Updated Analysis from Phase 2 KEYNOTE-158 Study. JCO, 39, 2565-2565. https://doi.org/10.1200/JCO.2021.39.15_suppl.2565
|
[22]
|
Overman, M.J., Lonardi, S., Wong, K.Y.M., et al. (2018) Durable Clinical Benefit with Nivolumab plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. JCO, 36, 773-779. https://doi.org/10.1200/JCO.2017.76.9901
|